Abstract
Objective: P-glycoprotein (P-gp), a transmembrane protein capable of transporting different substrates, has been identified among farmacologic variables that can modify the availability of antiretroviral drugs. P-gp has similar tissue distribution and similar substrates of cytochrome P450 subfamily 3A4, an enzyme system responsible for biotransformation of endogenous and exogenous substances. Methods: The aim of the paper is to analyse the role of P-gp as far as the pharmacokinetic of antiretroviral drugs is concerned and to evaluate possible strategies to overcome the interactions with these compounds. Results and conclusions: The therapeutic strategies that imply the modulation of P-gp may be clinically useful. Nevertheless, the usage of P-gp inhibitors in human beings should be addressed within clinical trials as higher concentrations of drugs in sanctuaries, usually protected by P-gp, might give rise to relevant toxicity.
Translated title of the contribution | P-glicoprotein and antiretroviral therapy |
---|---|
Original language | Italian |
Pages (from-to) | 149-154 |
Number of pages | 6 |
Journal | Giornale Italiano di Malattie Infettive |
Volume | 6 |
Issue number | 3 |
Publication status | Published - 2000 |
ASJC Scopus subject areas
- Microbiology (medical)